drugset / Trial / NCT02429440
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
RandomizedParallel-groupOpen-labelTreatment
Summary
Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer (RCC).
Timeline
- Start
- 2005-05
- Primary completion
- 2017-10
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NY-ESO-1 | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Intramuscular |